Joe Pantginis: Thanks for the color, Brian.
Operator: The next question comes from Jack Padovano of Stifel. Please go ahead.
Jack Padovano: This is Jack Padovano, calling in for Annabel Samimy. Thanks for taking a question. So again, I just wanted to touch briefly on the NASH resolution data from Tirzepatide synergy NASH trial. Just curious if those results change where you view THR beta receptor agonist kind of fitting into the treatment paradigm, given the more similar upstream liver fat impacts that both mechanisms have?
Brian Lian: Yes. Thanks, Jack. It doesn’t really change our view of the role of a targeted agent. We do think there’s going to be a lot of different therapies used in this population. The population is very heterogeneous to begin with and different patients will be better suited for different therapies. So we do see the targeted agents is remaining relevant for sure. That said, I think it would be naive to think that GLP-1 type therapeutics won’t be important in the treatment paradigm, potentially as a sort of a backbone in the overweight or the diabetic patient. But we still see there’s nice opportunity for a targeted agent.
Jack Padovano: Great. Thanks for the color.
Brian Lian: Thanks, Jack.
Operator: Next question comes from Justin Zelin of BTIG. Please go ahead.
Justin Zelin: Thanks for taking the question and congrats on the progress. Brian, I wanted to ask into the earlier guidance for — formulation of 2735 here being released ahead of guidance into level of interest or demand on behalf of patients for a subcu rather than an oral or just how we should be thinking about that?
Brian Lian: No. It’s just — thanks, Justin. It was just the trial was enrolled more quickly than expected and were no hiccups during the course of the study. And so we think we should have the data this quarter. Going to the demand, I mean it was just — the demand was reflected in the speed and size of the trial. It was really pretty easy to enroll.
Justin Zelin: That makes sense to me. And is it possible we could get the oral and the subcu data at — on the same time, on the same date?
Brian Lian: No, probably not. And we haven’t disclosed the sequence, just other than to say both will be this quarter.
Justin Zelin: Great. Thanks for taking my questions.
Brian Lian: Thanks, Justin.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Stephanie Diaz for any closing remarks.
Stephanie Diaz: Thank you again for your participation and continued support of Viking Therapeutics. We look forward to updating you again in the coming months. Have a great afternoon.
Operator: The conference has now concluded. Thank you for attending today’s presentation, and you may now disconnect.
